



SPARC/Sec/SE/2023-24/043

August 14, 2023

To,

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Ongoing litigations

With reference to the captioned matter, we would like to inform the Exchange that there are certain ongoing litigations that have been disclosed by the Company in its Annual Report for FY 2022-23 under contingent liabilities. However, due to the recent amendments to Regulation 30 of the SEBI Listing Regulations pursuant to the SEBI (Listing Obligations and Disclosure Requirements) (Second Amendment) Regulations, 2023, the same are now categorized as material information.

The brief details of the ongoing litigations as required under Regulation 30 of the SEBI Listing Regulations read with Circular no SEBI/HO/CFD-PoD-1/P/CIR2023/123 dated 13th July 2023 are provided in the enclosed **Annexure – I**.

The aforesaid information shall be made available on the Company's website at www.sparc.life

We request you to kindly take the above information on record.

For **Sun Pharma Advanced Research Company Limited**

Chetan Rajpara
Chief Financial Officer

Annexure - I

Brief Details of Direct & Indirect Tax Litigation

Sr. No.	Particulars	Details	
1	a)	Name of the opposing party,	Deputy Commissioner of Income Tax
		Court/ tribunal/agency where litigation is filed,	Commissioner of Income Tax (Appeals)
		Brief details of dispute/litigation	Disallowances / adjustments on account of transfer pricing, section 35(1)(iv), R&D capital expenditures, withholding tax on foreign remittances
	b)	Expected financial implications, if any, due to compensation, penalty etc.	Based on the facts of the case and prevailing law, no financial implication is anticipated
	c)	Quantum of claims, if any;	Rs. 8848 Lakhs (shown as contingent liability in financials)
2	a)	Name of the opposing party,	Commissioner of CGST & Central Excise
		Court/ tribunal/agency where litigation is filed,	Central Excise & Service Tax Appellate Tribunal (CESTAT) Mumbai
		Brief details of dispute/litigation	Applicability of service tax under reverse charge on the payment to overseas vendors
	b)	Expected financial implications, if any, due to compensation, penalty etc.	Based on the facts of the case and prevailing law, no financial implication is anticipated
	c)	Quantum of claims, if any;	Principal claim of Rs. 2302 Lakhs plus interest and penalty, if any (shown as contingent liability in financials)
3	a)	Name of the opposing party,	Commissioner of CGST & Central Excise
		Court/ tribunal/agency where litigation is filed,	Central Excise & Service Tax Appellate Tribunal (CESTAT) Mumbai
		Brief details of dispute/litigation	Rejection of Refund claim on technical grounds
	b)	Expected financial implications, if any, due to compensation, penalty etc.;	Based on the facts of the case and prevailing law, no financial implication is anticipated
	c)	Quantum of claims, if any;	Refund claim of Rs. 2754 Lakhs (shown as contingent liability in financials)